Several clinical trials have proven the safety and feasibility of recombinant granulocyte colony-stimulating factor in the induction treatment of primary acute myeloid leukemia. [1] [2] [3] An impact on overall survival has so far only been shown in relapsed disease where a significant reduction of neutropenia by granulocyte colony-stimulating factor support translated into improved survival due to reduction of the early-death rate. 4 Pegfilgrastim is a pegylated formulation of filgrastim with a sustained effect due to a negligible renal elimination 5 and a context-sensitive half-life due to a neutrophil-count-dependent clearance. To date, no data on pegfilgrastim in acute myeloid leukemia have been published. We report on our experience with this novel compound focusing on its pharmacokinetics and pharmacodynamics after induction polychemotherapy. These analyses were performed in the context of a phase II study and were approved by the local ethics committee. Prior to initiation of study medication, all patients gave their written informed consent. Seven days after the end of induction chemotherapy comprising high-dose cytarabine and mitoxantron, 6 mg of pegfilgrastim (Neulasta) was administered subcutaneously in patients showing complete blast clearance in routine bone marrow aspiration. A second injection was scheduled for those patients remaining leukopenic (that is, leukocytes o1 G l -1 ) 10 days after the first injection. Blood samples were obtained before the first application and then daily until leukocyte recovery. Pegfilgrastim plasma levels were measured by commercial granulocyte colony-stimulating factor ELISA (R&D Systems, GmbH, Wiesbaden-Nordenstadt, Germany).
Nineteen patients were included into the analysis. The median age was 62 years (range: 27-78 years; 7 male/12 female patients). The median peak plasma level of pegfilgrastim was 178 ng ml -1 and was reached within 2 days after injection ( Figure 1a) . Median half-life (T 1/2 ;) was 6 days, which strongly correlated to the absolute leukocyte count (Figure 1b) . Effective plasma levels of 42 ng ml -1 as defined by Yang et al. 6 were observed in all patients until day 14. Median time to leukocyte recovery was 8 days after application of pegfilgrastim.
Seven patients received a second injection of pegfilgrastim on day þ 10 (median) due to insufficient leukocyte recovery. A second application led to a median peak plasma level of 210 ng ml -1 . T 1/2 ; was dependent on leukocyte count; four of these seven patients had persistent neutropeniaFresulting in a T 1/2 ; of more than 12 days. Plasma levels were always in the effective range of 42 ng ml -1 (Figure 1d ). In the three patients with early leukocyte recovery after the second dose, T 1/2 ; was only 2 daysFclearly demonstrating the context-sensitive nature of pegfilgrastim half-life (Figure 1c) .
Pegfilgrastim was safe in our study, as all patients finished study medication as scheduled, and no side effects clearly related to the study drug were reported.
Concluding from these data, 6 mg of pegfilgrastim is sufficient to reach high peak plasma concentrations that are sufficient to maintain ample serum levels in all patients for over 14 days. Pegfilgrastim is a reasonable and cost-effective alternative to long-term conventional recombinant human granulocyte colony-stimulating factor in chemotherapy-induced leukopenia in patients with acute myeloid leukemia. However, from these data, no conclusion can be drawn with respect to its activity in shortening the time to neutrophil recovery. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML 4 NPM1 mutations characteristically generate mutants that localize aberrantly in the cytoplasm of leukaemic cells, 1 hence, the term NPMc þ (cytoplasmic-positive) AML. Cytoplasmic NPM accumulation is caused by changes of tryptophan(s) 288 and 290 (or only 290) and creation of a new nuclear export signal (NES) motif at the C-terminus of the NPM mutant. 5 Although the transforming potential of the NPM leukaemic mutants is yet to be proven, the observation that mutants retaining tryptophan 288 always combine with the strongest C-terminus NES motif reveals mutational selective pressure toward enhanced NPM export into cytoplasm, 6 pointing to this event as critical for leukaemogenesis. 4 About 80% of NPM1-mutated AML bear 'mutation A', 1, 4 that is, a tandem duplication of a TCTG tetranucleotide at positions 956-959 of NPM1. Intriguingly, tandem duplications seem to have played a role in evolution of biological diversity, 7 as expansions and contractions of repeats in critical genes are associated with great morphological diversity (for example,
